Next-generation precision antimicrobials: towards personalized treatment of infectious diseases
Empreu sempre aquest identificador per citar o enllaçar aquest ítem
http://hdl.handle.net/10045/69036
Títol: | Next-generation precision antimicrobials: towards personalized treatment of infectious diseases |
---|---|
Autors: | Fuente-Nunez, Cesar de la | Torres, Marcelo D.T. | Mojica, Francisco J.M. | Lu, Timothy K. |
Grups d'investigació o GITE: | Microbiología Molecular |
Centre, Departament o Servei: | Universidad de Alicante. Departamento de Fisiología, Genética y Microbiología |
Paraules clau: | Precision antimicrobials | Personalized treatment | Infectious diseases | Microbiota | CRISPR-Cas |
Àrees de coneixement: | Microbiología |
Data de publicació: | de juny-2017 |
Editor: | Elsevier |
Citació bibliogràfica: | Current Opinion in Microbiology. 2017, 37: 95-102. https://doi.org/10.1016/j.mib.2017.05.014 |
Resum: | Antibiotics started to be used almost 90 years ago to eradicate life-threatening infections. The urgency of the problem required rapid, broad-spectrum elimination of infectious agents. Since their initial discovery, these antimicrobials have saved millions of lives. However, they are not exempt from side effects, which include the indiscriminate disruption of the beneficial microbiota. Recent technological advances have enabled the development of antimicrobials that can selectively target a gene, a cellular process, or a microbe of choice. These strategies bring us a step closer to developing personalized therapies that exclusively remove disease-causing infectious agents. Here, we advocate the preservation of our beneficial microbes and provide an overview of promising alternatives to broad-spectrum antimicrobials. Specifically, we emphasize nucleic acid and peptide-based systems as a foundation for next-generation alternatives to antibiotics that do not challenge our microbiota and may help to mitigate the spread of resistance. |
Patrocinadors: | Cesar de la Fuente-Nunez is a Ramon Areces Foundation Fellow (Spain). Marcelo Der Torossian Torres is supported by Fundação de Amparo à Pesquisa do Estado de São Paulo (Brazil). Francisco J. M. Mojica is funded by the Spanish Ministerio de Economía y Competitividad (BIO2014-53029P) and the European Commission/Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (291815 Era-Net ANIHWA). Timothy Lu is supported by the National Institutes of Health, National Science Foundation, Defense Threat Reduction Agency, Defense Advanced Research Projects Agency, Center for Microbiome Informatics and Therapeutics, Kenneth Rainin Foundation, Koch Institute for Integrative Cancer Research, and Broad Institute of MIT and Harvard. |
URI: | http://hdl.handle.net/10045/69036 |
ISSN: | 1369-5274 (Print) | 1879-0364 (Online) |
DOI: | 10.1016/j.mib.2017.05.014 |
Idioma: | eng |
Tipus: | info:eu-repo/semantics/article |
Drets: | © 2017 Elsevier Ltd. |
Revisió científica: | si |
Versió de l'editor: | http://dx.doi.org/10.1016/j.mib.2017.05.014 |
Apareix a la col·lecció: | INV - Microbiología Molecular - Artículos de Revistas |
Arxius per aquest ítem:
Arxiu | Descripció | Tamany | Format | |
---|---|---|---|---|
2017_Fuente-Nunez_etal_CurrOpMicrobiol_final.pdf | Versión final (acceso restringido) | 1,43 MB | Adobe PDF | Obrir Sol·licitar una còpia |
2017_Fuente-Nunez_etal_CurrOpMicrobiol_accepted.pdf | Accepted Manuscript (acceso abierto) | 1,07 MB | Adobe PDF | Obrir Vista prèvia |
Tots els documents dipositats a RUA estan protegits per drets d'autors. Alguns drets reservats.